Stay updated with breaking news from Select Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adding a cardiovascular indication allows access by at risk Medicare patients to the obesity drug Wegovy. But health plans will likely implement strict coverage limits.
Data indicates cardiovascular protective benefits from taking the obesity drug Wegovy. It’s unclear if this data will convince payers to change their coverage policies.
In this episode, hosts take a deep dive into the study’s results, including secondary endpoints, and what it means for the care of patients with overweight or obesity and preexisting cardiovascular disease in real-world settings.
In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial.
In this episode of Don't Miss a Beat, hosts offer a breakdown of 3 trials of note from the upcoming ESC Congress 2023 and provide context around the recent announcement of topline results from the SELECT trial.